BMS Archive

Plant · Scientific monograph

Salix alba

White willow / Willow bark

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Pain Signaling Research, Inflammatory Pathways, Thermoregulation Research

Research overview

Historical use

Willow bark is one of the oldest analgesics known to humanity. Papyrus texts from ancient Egypt (c. 1550 BCE) describe its use for fever and pain. Hippocrates recommended it for fever and labour pains. The active principle, salicin, was first isolated in 1828 by French pharmacist Henri Leroux and purified by Italian chemist Raffaele Piria. Felix Hoffmann at Bayer then synthesised the acetylated derivative — acetylsalicylic acid — in 1897, giving birth to aspirin. Willow bark is thus the direct progenitor of one of the most prescribed drugs in history.

Modern research context

Standardised willow bark extract (120–240 mg salicin/day) demonstrated analgesic efficacy in chronic low back pain in a placebo-controlled RCT; pain reduction was comparable to rofecoxib 12.5 mg [2]. A 2001 RCT in osteoarthritis patients showed significant WOMAC pain subscale reduction versus placebo [3]. Unlike aspirin, willow bark does not irreversibly acetylate COX-1 and carries substantially lower gastrointestinal bleeding risk; platelet inhibition is minor and reversible [4]. A systematic review confirmed synergistic analgesic efficacy attributable to the flavonoid–salicin matrix rather than salicin alone [1]. A 2008 cohort study in gonarthrosis and coxarthrosis patients (n=436) showed clinically meaningful pain reduction with good tolerability [5]. The extract is standardised to salicin content (European Pharmacopoeia minimum 1.5%).

Adverse effects

GI intolerance (nausea, heartburn, diarrhoea) less common than with aspirin. Allergic reactions in aspirin-hypersensitive individuals (cross-reactivity — avoid in aspirin allergy). Rare: renal impairment with high-dose chronic use (salicylate nephropathy). Increased bleeding time. Reye's syndrome risk in children with viral illness (salicylate class effect — avoid in under-16s during viral illness). No antiplatelet effect as strong as aspirin.

Contraindications

Contraindicated in aspirin or salicylate hypersensitivity. Avoid in children under 16 with viral illness (Reye's syndrome risk — salicylate class). Avoid with anticoagulants (additive bleeding risk). Avoid in peptic ulcer disease and severe GERD. Caution before surgery. Avoid in third trimester of pregnancy (premature ductus arteriosus closure).

Clinical and phytochemical data

Used part

Bark of young branches (dried; aqueous or hydroethanolic extract)

Primary active compounds

  • Salicin (phenolic glycoside — primary prodrug; 1–12% in bark)

  • Salicortin and tremulacin (salicin esters; more potent anti-inflammatory than salicin alone)

  • Fragilin and populin (related phenolic glycosides)

  • Quercetin, naringenin, catechin, and epicatechin (flavonoids — contribute COX-2 and 5-LOX inhibition)

  • Chlorogenic acid and caffeic acid (phenolic acids)

  • Tannins (condensed proanthocyanidins)

Mechanism of action

Salicin is hydrolysed in the gut by β-glucosidase to saligenin (salicyl alcohol), which is then hepatically oxidised to salicylic acid — the primary active metabolite. Salicylic acid inhibits COX-1 and COX-2 non-selectively (unlike aspirin, without acetylation), reducing prostaglandin synthesis and producing analgesic, antipyretic, and anti-inflammatory effects. Inhibits NF-κB directly (aspirin-independent pathway) — reduces IL-6, TNF-α. Flavonoid fraction (quercetin, catechin) provides complementary COX-2 and 5-LOX inhibition, explaining the broader anti-inflammatory profile compared to purified salicylate alone. Tannins provide astringent and antipyretic effects at mucosal surfaces.

Pharmacokinetics

Absorption

Salicin itself is not the active compound — it functions as a prodrug. Human pharmacokinetic studies have directly characterised its systemic fate. In 10 healthy volunteers given willow bark extract corresponding to 240 mg salicin (two doses 3 h apart), salicylic acid appeared as the dominant serum salicylate within less than 2 h of ingestion [1]. Catechol — derived from the ester glycosides salicortin and tremulacin — was also identified in human serum as an additional absorbed metabolite, reaching a Cmax of 1.46 mg/L at 1.2 h after the dose [2].

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Salicylic acid (the primary active metabolite of salicin) is approximately 80–90% protein-bound to serum albumin at therapeutic concentrations, consistent with its behaviour as an endogenous-level salicylate. No specific distribution studies for salicin or its willow-bark metabolites have been conducted in humans.

Metabolism

Following oral ingestion, salicin is first hydrolysed by intestinal bacteria and brush-border glucosidases to release salicyl alcohol (saligenin), which is then oxidised to salicylic acid [1]. The ester glycosides salicortin and tremulacin undergo analogous hydrolysis with simultaneous release of catechol as a co-product [2]. In serum, 86% of total salicylates exist as salicylic acid, 10% as salicyluric acid, and 4% as gentisic acid — the same Phase II conjugation products as aspirin metabolism, but at far lower concentrations (equivalent to only 87 mg aspirin per therapeutic dose) [1].

Excretion

Renal elimination proceeds primarily as salicyluric acid (the dominant urinary form of salicylates) with minor contributions from gentisic acid and unchanged salicylic acid [1]. Catechol is excreted predominantly as catechol sulphate rather than as free catechol; unconjugated catechol was not detectable in human serum without prior enzymatic hydrolysis [2]. The short time to peak and predominantly renal elimination profile are consistent with a low accumulation risk at therapeutic willow bark doses.

Safety and interactions

Drug interactions

Anticoagulants (warfarin, heparin) — additive antiplatelet and anti-inflammatory effects; increased bleeding risk; monitor INR. Antiplatelet drugs (aspirin, clopidogrel) — additive bleeding; avoid combination. NSAIDs (ibuprofen, naproxen, diclofenac) — additive GI toxicity and nephrotoxicity. Methotrexate — salicylates reduce methotrexate renal clearance; toxicity risk. ACE inhibitors and antihypertensives — salicylates may blunt antihypertensive effect (renal prostaglandin inhibition). Uricosuric drugs (probenecid, sulfinpyrazone) — salicylates antagonise urate excretion at low doses.

Toxicity

Salicylate poisoning (salicylism) at high doses: tinnitus, nausea, hyperventilation, metabolic acidosis. Reye's syndrome (rare, potentially fatal encephalopathy and liver failure) with salicylate use in children during viral illness — class effect. Aspirin cross-sensitivity reactions: urticaria, bronchospasm, anaphylaxis in susceptible individuals. Chronic high-dose salicylate nephropathy possible with prolonged use.

Special precautions

Pregnancy

Avoid in the third trimester — salicylates cause premature closure of the ductus arteriosus and may prolong labour. Use in early pregnancy only under medical supervision.

Lactation

Salicylate is excreted in breast milk. Occasional use at low dietary doses has not been associated with documented harm in available case-level data; however, no controlled clinical safety data during breastfeeding exist; safety evidence during lactation is insufficient. Regular or high-dose use should be avoided.

Hepatic impairment

Salicylate conjugation (glycine, glucuronide) impaired in liver disease; accumulation risk. Reduce dose and monitor plasma salicylate levels in severe hepatic impairment.

Renal impairment

Salicylate primarily renally excreted; significant accumulation in renal failure. NSAIDs and salicylates reduce renal prostaglandin synthesis — may precipitate acute kidney injury. Avoid in moderate-to-severe renal impairment.

Sources and references

  1. [1] - Chrubasik S, Chrubasik C, Künzel O, Black A., "Evidence for effectiveness of herbal antirheumatic drugs.", Phytomedicine, 2007, PMID: 17373611
  2. [2] - Chrubasik S, Eisenberg E, Balan E, Weinberger T, Luzzati R, Conradt C., "Treatment of low back pain exacerbations with willow bark extract: a randomised double-blind study.", Am J Med, 2000, PMID: 10847560
  3. [3] - Schmid B, Lüdtke R, Selbmann HK et al., "Efficacy and tolerability of a standardised willow bark extract in patients with osteoarthritis: randomised placebo-controlled, double blind clinical trial.", Z Rheumatol, 2001, PMID: 11343283
  4. [4] - Vlachojannis J, Magora F, Chrubasik S., "Willow species and aspirin: different mechanism of actions.", Phytother Res, 2011, PMID: 20632299
  5. [5] - Beer AM, Wegener T., "Willow bark extract for gonarthrosis and coxarthrosis — results of a cohort study with a control group.", Phytomedicine, 2008, PMID: 18485707

Additional source links

Continue browsing